共 50 条
- [44] BE-POSITIVE: GEFITINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS HARBORING ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS. A COMBINED RETROSPECTIVE AND PROSPECTIVE ANALYSIS FROM ITALIAN PATIENTS. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S900 - S901
- [50] Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304) AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 432 - 439